inv-Resource-WhitePaper-ModularMultispecificAntibodies-01-1

Free white paperPDF • 8 min read

Modular Multispecific Antibodies

The Plug-and-Play Advantage of Invenra’s B-Body® and T-Body™ Platforms

549 molecules, six formats, and one purification process, with no molecule-specific optimization. See what platform consistency looks like when you put the whole dataset on the table.

Get the white paper
Submit the form and get it in your inbox right now

We respect your privacy and your inbox. No spam. No sharing of your information. Read our privacy policy.

 

The problem we tackle

Multispecific antibodies promise more. Making them reliably is the bottleneck.

Conventional multispecific antibody development relies on format-specific optimization. Each variable domain pair requires custom engineering of both the molecule and its production process. This creates delays as teams rebuild workflows for each candidate.

Yields shift with every engineering cycle, while purity often remains below 85%. And because this customization is only practical after lead selection, critical failure modes can emerge late (when they’re most expensive to address).

What you want instead is a platform that tests diverse variable domains and architectures in parallel. When you can reliably screen more than a thousand molecules at once, failure modes surface early rather than late.

The Main idea

Move the engineering out of the variable domain

Conventional multispecific antibody development relies on format-specific optimization. Each variable domain pair requires custom engineering of both the molecule and its production process. This creates delays as teams rebuild workflows for each candidate.

Yields shift with every engineering cycle, while purity often remains below 85%. And because this customization is only practical after lead selection, critical failure modes can emerge late (when they’re most expensive to address).

What you want instead is a platform that tests diverse variable domains and architectures in parallel. When you can reliably screen more than a thousand molecules at once, failure modes surface early rather than late.

Take a look inside What you’ll get in this paper

  • Why format-specific optimization is the real bottleneck in multispecific development, and where it breaks programs
  • How moving chain-pairing responsibility into the constant domains removes the need for molecule-by-molecule engineering
  • The full purity dataset across 549 molecules and six distinct formats, expressed and purified with identical protocols
  • How format-agnostic anti-CH1 capture and cation exchange polishing deliver consistent purity regardless of architecture
  • What consistent transient-to-stable performance means for CMC risk and for your CDMO relationship
  • Where the platform sits against traditional approaches on timeline, cost, and lead selection
inv-Resource-WhitePaper-ModularMultispecificAntibodies-01-1
inv-Resource-WhitePaper-ModularMultispecificAntibodies-01-1
inv-Resource-WhitePaper-ModularMultispecificAntibodies-01-1

Contributors Expert voices inside

806-Blackthorne-Ln-Arden-NC
Jessica Wiwczar, PhD

Former Senior Scientist II, Bioprocess And Early Development Protein Sciences

Invenra

806-Blackthorne-Ln-Arden-NC
Paul Guyett, PhD

Principal Scientist, Multispecific Antibody Therapeutic Programs

Invenra

806-Blackthorne-Ln-Arden-NC
Randy Bolger, PhD

Sales Director

Invenra

Get a copy sent to your inbox

Let’s get this paper to you. Submit the form and we’ll email it to you right now. And don’t worry, we care about privacy as much as you do. No spam. No sharing of your information. Read our privacy policy.

Submit the form and get it in your inbox right now

inv-Resource-WhitePaper-ModularMultispecificAntibodies-01-1